Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
BOSTON, Sept. 05, 2017 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast corporate presentations at the following investor conferences in September:
- A fireside chat at Morgan Stanley’s Global Healthcare Conference in New York City on Tuesday, September 12, 2017 at 12:55 p.m. EDT.
- Cantor Fitzgerald’s Global Healthcare Conference in New York City on Monday, September 25, 2017 at 4:45 p.m. EDT.
- Ladenburg Thalmann’s 2017 Healthcare Conference in New York City on Tuesday, September 26 at 11:30 a.m. EDT.
Live audio webcasts of the presentations will be accessible from Keryx Biopharmaceuticals’ website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentations.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with kidney disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617-466-3511 [email protected]
